FULC

Fulcrum is a clinical-stage biopharma, not a business you value on earnings — FY2025 revenue was $0.00 (the FY2024 $80.0M was a one-time collaboration upfront that did not recur, driving the '-100%' optics), and it posted a -$74.9M net loss with -$60.1M operating cash outflow. The whole thesis rides on one asset: pociredir for sickle cell disease. The balance sheet is the reason to keep it alive as a speculation — $198M cash (up 239% YoY), $349M equity against just $17.3M total liabilities (0.05x liabilities/equity) and effectively no debt. Against ~$60M annual burn that is roughly three years of runway, though the 23.4% YoY share-count increase and management's explicit warning that 'expenses will increase substantially' as they run a registration-enabling trial mean further dilution is close to certain.

The clinical data disclosed in the February 2026 10-K is the strongest part of the story and materially better than the raw financials suggest. The 20 mg PIONEER cohort showed mean absolute HbF rising from 7.1% to 19.3% at 12 weeks, 58% of patients hitting ≥20% HbF (a level real-world data links to ~90% experiencing zero VOCs), hemoglobin up 1.1 g/dL, broad improvement in hemolysis markers, and six VOCs versus ~16 expected — all with no treatment-related serious adverse events and no discontinuations. For a benign-hematology asset, that is a clean efficacy-plus-safety signal heading into an End-of-Phase FDA meeting.